Arvinas to Present Initial Data from Ongoing Clinical Trials and a Pipeline Update at the 2nd Targeted Protein Degradation Summit
- Platform Presentation to Include Initial Safety, Tolerability, and Pharmacokinetic Data from Ongoing Phase 1 Trials
- Neuroscience Presentation to Include Data from Preclinical Tau and Alpha-Synuclein Programs
Dr. Taylor’s presentation is
Arvinas Presentations at the 2nd Targeted Protein Degradation Summit
- Moving PROTAC® Protein Degraders from the Laboratory to the Clinic
Ian Taylor, Ph.D., CSO
° Date and Time:
October 23– 11:30 AM
- Keynote Plenary: Accelerating Emerging Protein Degraders into the Clinic: Industry Leaders Panel Discussion
Randy Teel, Ph.D., VP, Corporate Development
° Date and Time:
October 24– 9:30 AM
- Discovery of Brain Penetrant PROTAC®Degrader Molecules that Target Pathologic Tau Protein Species
Angela Cacace, Ph.D., VP, Neuroscience and Platform Biology
° Date and Time:
October 24– 11:30 AM
ARV-110 is an orally-bioavailable PROTAC® protein degrader designed to selectively target and degrade the androgen receptor (AR). ARV-110 is being developed as a potential treatment for men with metastatic castration-resistant prostate cancer (mCRPC). Arvinas’ Phase 1 trial of ARV-110 will assess its safety, tolerability, and pharmacokinetics, and will also include measures of anti-tumor activity and pharmacodynamic readouts as secondary endpoints.
ARV-110 has demonstrated activity in preclinical models of AR mutation or overexpression, both common mechanisms of resistance to currently available AR-targeted therapies. Arvinas believes the differentiated pharmacology of ARV-110, including its iterative mechanism of action, has the potential to translate into meaningful clinical benefit for patients.
ARV-471 is a PROTAC® protein degrader designed to specifically target and degrade the estrogen receptor (ER). Arvinas’ Phase 1 trial of ARV-471 will assess its safety, tolerability, and pharmacokinetics, and will also include measures of anti-tumor activity and pharmacodynamic readouts as secondary endpoints.
In preclinical studies, ARV-471 demonstrated near-complete ER degradation in tumor cells, induced robust tumor shrinkage when dosed as a single agent in multiple ER-driven xenograft models, and showed superior anti-tumor activity as a single agent and in combination with a CDK4/6 inhibitor when compared to a standard of care agent, fulvestrant (as a single agent and in combination with a CDK4/6 inhibitor).
This press release contains forward-looking statements that involve substantial risks and uncertainties, including statements regarding the development and regulatory status of our product candidates, our scheduled participation at the 2nd
We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make as a result of various risks and uncertainties, including but not limited to: whether we will be able to successfully conduct Phase 1 clinical trials for ARV-110 and ARV-471, complete other clinical trials for our product candidates on our expected timelines, or at all, whether our cash resources will be sufficient to fund our foreseeable and unforeseeable operating expenses and capital expenditure requirements on our expected timeline and other important factors discussed in the “Risk Factors” sections contained in our quarterly and annual reports on file with the
Will O’Connor, Stern Investor Relations
Source: Arvinas Inc.